Showing results (11-20 of 174) with videos related to
Sort By:
Pageof 18
Bulletin Du Cancer|April 9, 2008
[HER2 and topoisomerase II alpha: useful clinical markers in breast cancer]Denis Larsimont, Virginie Durbecq, Ahmad Awada, et al.Future Oncology (London, England)|February 25, 2011
Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancerCatherine Oakman, Erica Moretti, Libero Santarpia, et al.Current Opinion in Obstetrics & Gynecology|May 7, 2004
Chemotherapy for metastatic breast cancerLaura Biganzoli, Alessandro Minisini, Matti Aapro, et al.Advances in Experimental Medicine and Biology|March 19, 2016
Metabolomics in Breast Cancer: Current Status and PerspectivesChristopher D Hart, Leonardo Tenori, Claudio Luchinat, et al.Nature Reviews. Clinical Oncology|December 10, 2009
Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancerPhilippe L Bedard, Angelo Di Leo, Martine J Piccart-GebhartClinical Breast Cancer|November 12, 2002
Resistance to trastuzumab: a necessary evil or a temporary challenge?Fatima Cardoso, Martine J Piccart, Virginie Durbecq, et al.Oncology|November 8, 2002
Current status of HER2 testingAngelo Di Leo, Mitch Dowsett, Bruce Horten, et al.Cancer Management and Research|December 29, 2010
Role of lapatinib in the first-line treatment of patients with metastatic breast cancerCatherine Oakman, Marta Pestrin, Elena Zafarana, et al.European Journal of Cancer (Oxford, England : 1990)|August 19, 2007
Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients -- a jungle?Laura Biganzoli, Sara Licitra, Wederson Claudino, et al.Cancer Treatment Reviews|September 18, 2009
The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patientsCatherine Oakman, Erica Moretti, Francesca Galardi, et al.Pageof 18